Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity

Targeting Hsp90 is an effective strategy for cancer therapy. TAS-116 has been approved for the treatment of gastrointestinal stromal tumors. Our previous studies identified a series of pyrazole derivatives as covalent Hsp90 inhibitors that allosterically disrupt the Hsp90-Cdc37 interaction. Here, th...

Full description

Saved in:

Bibliographic Details
Main Author:	Zi-Wen Feng (14608411) (author)
Other Authors:	Li Li (14993) (author), Shi-Duo Zhang (14608414) (author), Ying-Ji Wang (21228156) (author), Jia-Yue Pei (21228159) (author), Nan-Nan Chen (15198729) (author), Bei-Duo Wu (15198735) (author), Qiu-Ling Zheng (13119805) (author), Qi-Dong You (294415) (author), Xiao-Ke Guo (459015) (author), Xiao-Li Xu (404540) (author)
Published:	2025
Subjects:	Biochemistry Medicine Cell Biology Pharmacology Biotechnology Sociology Cancer Chemical Sciences not elsewhere classified Information Systems not elsewhere classified previous studies identified novel mechanistic approach gastrointestinal stromal tumors collective findings underscore new covalent warhead 39 </ b covalent hsp90 inhibitors 50 </ sub covalent hsp90 50 μm therapeutic promise targeted disruption pyrazole derivatives pyrazole compounds knockout counterparts hsp90 regulators effective strategy cancer therapy allosterically disrupt (< b
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity

Similar Items